Stammzelltherapie bei Pyoderma gangraenosum

Zusammenfassung

Das Pyoderma gangraenosum ist ein seltene autoinflammatorische [1] neutrophilenreiche Dermatitis/Pannikulitis. Wir stellen eine 59-jährige Patientin vor, die an einem Mammakarzinom behandelt wurde und nachfolgend einen ausgedehnten Hautdefekt entwickelte. Über ein Jahrzehnt später konnte dann erstmals ein Pyoderma gangraenosum diagnostiziert werden. Trotz einer konsequenten immunsuppressiven Therapie kam es zur weiteren Ausdehnung des Befunds. Unter der Anwendung einer Stammzelltherapie und dem Einsatz von Biologika verkleinert sich der Befund gegenwärtig langsam.

Abstract

Pyoderma gangrenosum is a rare autoinflammatory [1] neutrophil-rich dermatitis/panniculitis. We present a 59-year-old female patient who was treated for breast cancer and subsequently developed an extensive skin defect. More than ten years later pyoderma gangrenosum was diagnosed for the first time. Despite consistent immunosuppressive therapy, the findings were further extended. With the use of stem cell therapy and biologics, the findings are currently slowly decreasing.

Publication History

Article published online:
08 May 2024

• Literatur

• 1 Maverakis E, Marzano AV, Le ST. et al. Pyoderma gangrenosum. Nat Rev Dis Primers 2020; 6: 81
• 2 Maronese CA, Pimentel MA, Li MM. et al. Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments. Am J Clin Dermatol 2022; 23: 615-634
• 3 Agarwal A, Andrews JM. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther 2013; 38: 563-572
• 4 Wenzel J, Gerdsen R, Phillipp-Dormston W. et al. Topical treatment of pyoderma gangraenosum. Dermatology 2002; 205: 221-223
• 5 Costa G, İlgün S, Pisani D. et al. A Rare Complication Following Breast Conserving Surgery: Pyoderma Gangrenosum. Eur J Breast Health 2023; 19: 331-334
• 6 Dissemond J, Marzano AV, Hampton PJ. et al. Pyoderma Gangrenosum: Treatment Options. Drugs 2023; 83: 1255-1267
• 7 Charles CA, Leon A, Banta MR. et al. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol 2007; 46: 1095-1099
• 8 McPhie ML, Kirchhof MG. Pyoderma gangrenosum treated with secukinumab: A case report. SAGE Open Med Case Rep 2020; 8: 2050313X20940430
• 9 Tee MW, Avarbock AB, Ungar J. et al. Rapid resolution of pyoderma gangrenosum with brodalumab therapy. JAAD Case Rep 2020; 6: 1167-1169
• 10 Niebergall-Roth E, Frank NY, Ganss C. et al. Skin-derived ABCB5(+) mesenchymal stem cells for high-medical-need inflammatory diseases: From discovery to entering clinical routine. Int J Mol Sci 2022; 24: 66
• 11 RHEACELL GmbH & Co. KG. Technologie. 2023 Accessed December 19, 2023 at: https://www.rheacell.com/de/technologie/